Oral candidiasis is the main symptom that often appears in patients with Human Immunodeficiency Virus (HIV) / Acquired Immune Syndrome (AIDS). Recent studies reported that some bacteria causing oral candidiasis are resistant to antifungal drugs. Describing nystatin profile against candida species in HIV / AIDS patients with oral candidiasis. Twenty-nine subjects were divided into 2 groups based on sex (23 male subjects and 6 female subjects). Subjects carried out tissue culture procedure and were tested for sensitivity to fluconazole and nystatin. The analysis was conducted by comparing sex and type of infecting bacteria. Statistical analysis used chi-square test, fisher, or ANOVA with 95% CI with p <0.05. The average age of male and female subjects was 43.15 ± 3.67 years and 40.02 ± 10.23 years, respectively, with age range of 18-65 years. Recurrent oral candidiasis in male and female patients was 65.22% and 83.33%, respectively (p = 0.079). Subjects were resistant to fluconazole as much as 77.50% in men and 61.54% in women (p = 0.823). On the other hand, subjects sensitive to nystatin were 92.50% in men and 92.31% in women (p = 0.167). Fluconazole was resistant to Candida albicans (68.00%) and non-Candida albicans (78.57%) (p = 0.048), while nystatin was sensitive to Candida albicans (92.00%) and non-Candida albicans (92.86%) (p = 0.791). Most subjects were resistant to fluconazole, while the majority of subjects were sensitive to nystatin.
Nystatin, fluconazole, oral candidiasis, Candida albicans, HIV/AIDS.
© The Author(s) 2019. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.